Full-year results and business updateClinical proof of principle obtained in Phase I adjuvant head and neck cancer trial with individualized ...

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...

The only other Ford GT Competition Prototype Roadster in existence, GT/108, was sold at the 2019 RM Sotheby’s Monterey ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly intensifying in France’s Island of La ...

By Clare Nuttall in Almaty In the changing world order, Kazakhstan continues to pursue the multi-vector foreign policy that ...

OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category Oxford, UK – 21 March 2025: OXB (LSE: ...

Just as it did with Sweden, Signal is refusing to stay in a territory that undermines its encryption strategy, arguing that a ...

The 5G Broadcast Strategic Task Force, made up of broadcasters from a number of European broadcasting markets and supported ...

Rising temperatures are driving the expansion of the tiger mosquito into Europe and increasing the prevalence of toxic plants ...

Speaking at SXSW 2025, Druckmann said there is "an escalation of numbers and types of infected, but also, as you see in the trailer, an escalation of the vector of how this thing spreads." ...

Strasbourg (France), March 11, 2025, 5:45 p.m. CET – Transgene (Euronext ... Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells. The ...